Differences in gene expression between noninvasive and invasive transitional cell carcinoma of the human bladder using complementary deoxyribonucleic acid microarray: Preliminary results

Elsamman, Essam; Fukumori, Tomoharu; Ewis, Ashraf A.; Ali, Nermin; Kajimoto, Kazuaki; Shinohara, Yasuo; Ishikawa, Mitsuru; Takahashi, Masayuki; Nishitani, Masaaki; Baba, Yoshinobu; Kanayama, Hiro‐omi

doi:10.1016/j.urolonc.2005.07.011

Cited by 18 publications

(10 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study is a logic follow-up to identify molecular markers in very early stage of primary NMIBC that may predict its recurrence. If we define upregulated or downregulated genes of our study, several of them are common to genes published by other authors, but in general the analogy of the genes, presented here, is not so extensive with other studies [7,8,[10][11][12][13][14][15][16]. It may be caused by unique provenance 1, 2, 3, 12, 14, 15, 16, and 22, see Table 2).…”

Section: Discussionmentioning

confidence: 86%

“…Several expression microarray studies have been performed for prognostic purposes in primary NMIBC, but none has shown sufficient clinical evidence to clinical usage. Most of them are based on identification of genes in transgenic mouse models [10], specific bladder cancer cell lineages [11], biological material from advanced tumors comparing gene expression in invasive stage of tumor disease [12,13,14] or usage of different molecular biological methods [15].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prediction of recurrence in low and intermediate risk non-muscle invasive bladder cancer by real-time quantitative PCR analysis: cDNA microarray results

Mareš¹,

Szakácsová²,

Soukup³

et al. 2013

neo

View full text Add to dashboard Cite

The aim of the study was to define specific genetic profile in Ta and T1 urinary bladder carcinoma patients with and without recurrence by gene expression microarrays. Eleven patients with the time to recurrence shorter than one year (patients with recurrence) and 11 patients with time to recurrence longer than 4 years (patients without recurrence) were enrolled.Data from microarrays were subjected to a panel of statistical analyses to identify bladder cancer recurrence-associated gene signatures. Initial screening using the GeneSpring and Bioconductor software tools revealed a putative set 47 genes differing in gene expression in both groups. After the validation, 33 genes manifested significant differences between both groups. The significant expression was observed in the group of patients without recurrence by 30 genes of which the highest differences were detected by ANXA1, ARHGEF4, FLJ32252, GNE, NINJ1, PRICKLE1, PSAT1, RNASE1, SPTAN1, SYNGR1, TNFSF15, TSPAN1, and WDR34. These genes code for signal transduction, vascular remodeling and vascular endothelial growth inhibition mainly. In the group with recurrence, 3 genes had significant differences, the highest differences were identified by two genes (PLOD2 and WDR72).Loci of genes with significant changes of gene expression were located on characteristic chromosomes for bladder cancer: 7 loci on chromosome 9, 8 loci on chromosomes 1, 2, 3, 12, 14, 15, 16, and 22. We have selected and validated 15 genes that are differentially expressed in superficial bladder cancer. We hope that this cohort of genes will serve as a promising pool of candidate biomarkers for early stage bladder cancer. Our results indicate that it may be possible to identify patients with a low and high risk of disease recurrence at an early stage using a molecular profile. Key words: bladder cancer, non-muscle invasive urothelial tumors, gene expression microarraysBladder cancer (BC) is the sixth most frequent solid tumor in men and thirteenth in women in Czech Republic with 1827 and 650 new cases in 2005, respectively [1] and 375.000 new cases and 145.000 deaths worldwide annually [2]. Urothelial carcinoma (UC) is a heterogenous neoplasm manifesting either non-muscle invasive bladder cancer (NMIBC) -Ta, T1 and Tis by approximatelly 75 % newly diagnosed cases or muscle invasive (T2-T4) and metastatic tumor (25 %) [3,4]. After initial treatment of NMIBC by transurethral resection (TURB) up to 80 % of patients develop recurrences. From 10 % to 15 % of them progress to muscle invasive cancer [5,6]. For treatment and follow up of patients it is crucial to predict the recurrence and progression potential of non-muscle invasive bladder cancer. Therefore new methods are engaged to identify new prognostic markers based on the molecular nature of the tumor development and recurrence [7,8].The objective of our study was to identify the genes differing in gene expression in tumors with and without recurrence. Among the genes it might be determined a gene or several genes serving as factors for furt...

show abstract

Section: Discussionmentioning

confidence: 86%

Section: Discussionmentioning

confidence: 99%

Prediction of recurrence in low and intermediate risk non-muscle invasive bladder cancer by real-time quantitative PCR analysis: cDNA microarray results

Mareš¹,

Szakácsová²,

Soukup³

et al. 2013

neo

View full text Add to dashboard Cite

show abstract

“…Target validation of synuclein by immunohistochemistry on tissue arrays (n ¼ 294) validated its association with tumor staging and outcome. Other studies using cDNA arrays confirmed genetic signatures including FGFR3 or AIG1 as associated with Ta disease with significant upregulation of 34 genes associated with muscle invasive bladder cancer, including VEGFC or MMP7 and others related to extracellular matrix degradation, immune responses, cell cycling, and angiogenesis [85].…”

Section: High-throughput Transcript Profilingmentioning

confidence: 86%

Molecular markers in bladder cancer

Shariat

Karam

Lerner

2008

Current Opinion in Urology

View full text Add to dashboard Cite

Molecular biology is paramount to our understanding of bladder cancer pathogenesis. The search for new markers, and elucidating cross-talk between markers in different pathways, is warranted. Molecular markers have the potential benefit of improving detection, prognosis and treatment of bladder cancer. In addition, understanding the molecular profile of the individual patient could usher us into a new era of improving prediction of the natural history of the disease and providing a more personalized and tailored treatment. Prospective trials are still needed, however, to objectively establish the true benefit of these markers in prognostic and therapeutic arenas.

show abstract

“…A total of 28 bladder cancer gene signatures from 14 studies (7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20), as well as 11 nonbladder cancer-derived gene signatures devised for various purposes (22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32) were extracted from the literature (Supplementary Table S1). GeneSymbols in the signatures were updated using the official HGNC GeneSymbols downloaded from the HGNC Web site (33).…”

Section: Gene Signaturesmentioning

confidence: 99%

“…A large number of molecular markers have been described in the literature (6), but few have entered into clinical decision making. In recent years, several investigations have used genome-wide gene expression analyses to define specific gene expression signatures associated with both urothelial cancer biology and the clinical course of the disease (7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20). Many of these have the potential to be of great clinical value.…”

mentioning

confidence: 99%

Prediction of Stage, Grade, and Survival in Bladder Cancer Using Genome-wide Expression Data: A Validation Study

Lauss

Ringnér

Höglund

2010

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: To evaluate performances of published gene signatures for the assessment of urothelial carcinoma.Experimental Design: We evaluated 28 published gene signatures designed for diagnostic and prognostic purposes of urothelial cancer. The investigated signatures include eight signatures for stage, five for grade, four for progression, and six for survival. We used two algorithms for classification, nearest centroid classification and support vector machine, and Cox regression to evaluate signature performance in four independent data sets.Results: The overlap of genes among the signatures was low, ranging from 11% among stage signatures to 0.6% among survival signatures. The published signatures predicted muscle-invasive and high-grade tumors with accuracies in the range of 70% to 90%. The performance for a given signature varied considerably with the validation data set used, and interestingly, some of the best performing signatures were not designed for the tested classification problem. In addition, several nonbladder-derived gene signatures performed equally well. Large randomly selected gene signatures performed better than the published signatures, and by systematically increasing signature size, we show that signatures with >150 genes are needed to obtain robust performance in independent validation data sets. None of the published survival signatures performed better than random assignments when applied to independent validation data.Conclusion: We conclude that gene expression signatures with >150 genes predict muscle-invasive growth and high-grade tumors with robust accuracies. Special considerations have to be taken when designing gene signatures for outcome in bladder cancer. Clin Cancer Res; 16(17); 4421-33. ©2010 AACR.

show abstract

Differences in gene expression between noninvasive and invasive transitional cell carcinoma of the human bladder using complementary deoxyribonucleic acid microarray: Preliminary results

Cited by 18 publications

References 27 publications

Prediction of recurrence in low and intermediate risk non-muscle invasive bladder cancer by real-time quantitative PCR analysis: cDNA microarray results

Prediction of recurrence in low and intermediate risk non-muscle invasive bladder cancer by real-time quantitative PCR analysis: cDNA microarray results

Molecular markers in bladder cancer

Prediction of Stage, Grade, and Survival in Bladder Cancer Using Genome-wide Expression Data: A Validation Study

Contact Info

Product

Resources

About